IL256264A - Methods of modulating cytosolic dna surveillance molecules - Google Patents

Methods of modulating cytosolic dna surveillance molecules

Info

Publication number
IL256264A
IL256264A IL256264A IL25626417A IL256264A IL 256264 A IL256264 A IL 256264A IL 256264 A IL256264 A IL 256264A IL 25626417 A IL25626417 A IL 25626417A IL 256264 A IL256264 A IL 256264A
Authority
IL
Israel
Prior art keywords
methods
cytosolic dna
dna surveillance
modulating
surveillance molecules
Prior art date
Application number
IL256264A
Other languages
English (en)
Hebrew (he)
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of IL256264A publication Critical patent/IL256264A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL256264A 2015-06-26 2017-12-12 Methods of modulating cytosolic dna surveillance molecules IL256264A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185230P 2015-06-26 2015-06-26
PCT/EP2016/064613 WO2016207314A2 (en) 2015-06-26 2016-06-23 Methods of modulating cytosolic dna surveillance molecules

Publications (1)

Publication Number Publication Date
IL256264A true IL256264A (en) 2018-02-28

Family

ID=56235815

Family Applications (1)

Application Number Title Priority Date Filing Date
IL256264A IL256264A (en) 2015-06-26 2017-12-12 Methods of modulating cytosolic dna surveillance molecules

Country Status (22)

Country Link
US (1) US20190233825A1 (cg-RX-API-DMAC7.html)
EP (1) EP3313376A2 (cg-RX-API-DMAC7.html)
JP (1) JP2018518511A (cg-RX-API-DMAC7.html)
KR (1) KR20180021874A (cg-RX-API-DMAC7.html)
CN (1) CN108472255A (cg-RX-API-DMAC7.html)
AR (1) AR105160A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016282879A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017028121A2 (cg-RX-API-DMAC7.html)
CA (1) CA2990526A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017003373A1 (cg-RX-API-DMAC7.html)
CR (1) CR20180003A (cg-RX-API-DMAC7.html)
DO (1) DOP2017000313A (cg-RX-API-DMAC7.html)
HK (1) HK1256128A1 (cg-RX-API-DMAC7.html)
IL (1) IL256264A (cg-RX-API-DMAC7.html)
MX (1) MX2017017141A (cg-RX-API-DMAC7.html)
PE (1) PE20181208A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017502413A1 (cg-RX-API-DMAC7.html)
RU (1) RU2018102915A (cg-RX-API-DMAC7.html)
SG (1) SG10201913395VA (cg-RX-API-DMAC7.html)
TW (1) TW201710509A (cg-RX-API-DMAC7.html)
UY (1) UY36756A (cg-RX-API-DMAC7.html)
WO (1) WO2016207314A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3490598A1 (en) 2016-07-26 2019-06-05 Bayer Animal Health GmbH Increased fertility in bovine species
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155950A (en) * 1874-10-13 Improvement in hand-saws
CA2560114A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
EP1003531B1 (en) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
AU2001296354A1 (en) * 2000-09-25 2002-04-02 Baylor College Of Medicine Improved system for regulation of transgene expression
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
CL2004001293A1 (es) * 2003-05-29 2005-05-06 Schering Plough Ltd Composicion farmaceutica que comprende compuestos antibacterianos como florfenicol, tiamfenicol, cloramfenicol en combinacion con al menos un portador seleccionado de triacetina, dimetilacetamida o una mezcla de ellas; y su uso en el tratamiento de u
EP1786461A4 (en) * 2004-08-13 2010-03-03 Univ Pennsylvania ANTIBIOTICINESIS-FREE DNA VACCINES
AU2005271246A1 (en) * 2004-08-13 2006-02-16 The Trustees Of The University Of Pennsylvania Methods for constructing antibiotic resistance free vaccines
US20120064151A1 (en) * 2009-05-14 2012-03-15 Bayer Animal Health Gmbh Enhanced immune response in avian species
JP6058550B2 (ja) * 2010-12-22 2017-01-11 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ウシの種における免疫応答の増強
BR112013029968A2 (pt) * 2011-05-26 2017-01-31 Intervet Int Bv oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, vacina para prevenir ou combater uma doença infecciosa, e, método para a detecção de oligodesoxinucleotídeos imunoestimulatórios
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
MX2016010993A (es) * 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.

Also Published As

Publication number Publication date
PH12017502413A1 (en) 2018-06-25
AR105160A1 (es) 2017-09-13
UY36756A (es) 2017-01-31
PE20181208A1 (es) 2018-07-23
CL2017003373A1 (es) 2018-06-29
AU2016282879A1 (en) 2018-01-18
TW201710509A (zh) 2017-03-16
BR112017028121A2 (pt) 2018-09-04
MX2017017141A (es) 2018-03-09
CN108472255A (zh) 2018-08-31
WO2016207314A3 (en) 2017-02-09
EP3313376A2 (en) 2018-05-02
CR20180003A (es) 2018-03-20
CA2990526A1 (en) 2016-12-29
DOP2017000313A (es) 2018-02-28
KR20180021874A (ko) 2018-03-05
WO2016207314A2 (en) 2016-12-29
RU2018102915A (ru) 2019-07-29
RU2018102915A3 (cg-RX-API-DMAC7.html) 2019-12-05
HK1256128A1 (zh) 2019-09-13
US20190233825A1 (en) 2019-08-01
SG10201913395VA (en) 2020-03-30
JP2018518511A (ja) 2018-07-12

Similar Documents

Publication Publication Date Title
IL288622A (en) DNA fragmentation pattern analysis suitable clean
SG11201911430PA (en) Novel nucleic acid molecules
IL259421B (en) ror - gamma modulators
SG11201704681QA (en) Artificial nucleic acid molecules
SG10201913629VA (en) Artificial nucleic acid molecules
GB201521858D0 (en) Small molecules
GB201412659D0 (en) Molecules
EP3157573A4 (en) Alternative nucleic acid molecules and uses thereof
EP3157572A4 (en) Alternative nucleic acid molecules and uses thereof
GB201412658D0 (en) Molecules
HUE049094T2 (hu) Sejtmentes DNS kvantifikálási módszerei
LT3094731T (lt) Sacharidais modifikuotos nukleorūgšties molekulės
ZA201605332B (en) Trpa1 modulators
PL3204749T3 (pl) Analizator cieczy
GB201516260D0 (en) System for secure analysis of datasets
IL256264A (en) Methods of modulating cytosolic dna surveillance molecules
IL256694A (en) Fusion molecules
PL3134882T3 (pl) Sposoby i układy do modulowania aktywacji samoalarmujących etykiet
IL255081B (en) Identification of nucleic acid molecules
SG11201607445QA (en) Methods of modulating wars2
PT3377106T (pt) Modulação da ciliogénese
GB201607636D0 (en) Molecules & method
GB201508443D0 (en) Methods of identifying USP-binding compounds
GB201400388D0 (en) Assessment of assemblies